Tablets, Lozenges, Or Pills Patents (Class 424/464)
With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.) (Class 424/465)
Effervescent (Class 424/466)
Printed, embossed, grooved, or perforated (Class 424/467)
Sustained or differential release type (Class 424/468)
Coated pills or tablets (Class 424/474)
  • Manufacture of tablet having immediate release region and sustained release region
    Patent number: 8313768
    Abstract: In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape including a powder blend containing a pharmaceutically active agent and a thermally-sensitive material; and (b) applying energy in different amounts to different regions of the tablet shape to form the tablet in a manner such that: (i) a first region of the tablet shape is exposed to said energy for a sufficient period of time to melt the thermally-sensitive material within the first region to form said modified release region of said tablet; and (ii) a second region of said tablet shape is not so exposed to the energy such that said second region forms the immediate release region of said tablet.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: November 20, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Leo B. Kriksunov, Harry S. Sowden, Joseph R. Luber, Frank J. Bunick
  • Oral antidepressant formulation with reduced excipient load
    Patent number: 8313766
    Abstract: Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: November 20, 2012
    Inventors: Andrew Chen, Hailiang Chen, James Cecil Free, Majid Keshtmand, Mohammed Abdul Rahman, Sally A. Look
  • Pharmaceutical compositions and methods for the oral delivery of insulin
    Patent number: 8309123
    Abstract: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. The pharmaceutical compositions contain the at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed in a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: November 13, 2012
    Inventors: Farid Bennis, Jean Jacques Serrano
  • Solid pharmaceutical dosage form
    Patent number: 8309613
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: November 13, 2012
    Assignee: AbbVie Inc.
    Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
  • Delayed release tablet with defined core geometry
    Patent number: 8309124
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: November 13, 2012
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Oxymorphone controlled release formulations
    Patent number: 8309122
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: November 13, 2012
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Nanoparticulate quinazoline derivative formulations
    Patent number: 8309133
    Abstract: The present invention is directed to nanoparticulate quinazoline derivative compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate quinazoline derivative particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hyperproliferative disorders, such as cancer and other neoplastic diseases. The compositions may include quinazolinamine derivatives such as erlotinib or a salt thereof.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: November 13, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Pharmaceutical compositions comprising fluvastatin
    Patent number: 8303987
    Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: November 6, 2012
    Assignee: Novartis AG
    Inventors: Oskar Kalb, Stephen Valazza
  • Hydrophilic/lipophilic polymeric matrix dosage formulation
    Patent number: 8303986
    Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 6, 2012
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
  • Nitrite formulations and their use as nitric oxide prodrugs
    Patent number: 8303995
    Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Methods of reducing triglycerides or reducing C-reactive protein levels are also provided.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: November 6, 2012
    Assignees: Board of Regents, The University of Texas System, Neogenis Laboratories, Inc.
    Inventors: Nathan Scott Bryan, Janet Zand
  • PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND PREPARATION METHOD THEREOF
    Publication number: 20120276198
    Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.
    Type: Application
    Filed: December 25, 2009
    Publication date: November 1, 2012
    Applicant: INNOPHARMAX INC.
    Inventors: Weihua Hao, Jongjing Wang, Huiyun Chen
  • Effervescent oral opiate dosage forms and methods of administering opiates
    Patent number: 8298577
    Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Cephalon, Inc.
    Inventor: Derek Moe
  • Posterior segment drug delivery
    Patent number: 8298578
    Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 30, 2012
    Assignee: Forsight Vision4, Inc.
    Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela MacFarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Douglas Sutton
  • Cellulose-based fine core particle and process for producing the same
    Patent number: 8298585
    Abstract: It is an object of the present invention to provide a fine core particle, which comprises a coating layer having a uniform thickness, and which can be used to produce, at a high yield, a small granule causing no sandy feeling in the oral cavity when the fine core particle is applied to a fine granule or an orally-disintegrating tablet. According to the present invention, there is provided a core particle, which comprises 50% by mass or more of microcrystalline cellulose, and which has a mean particle diameter of less than 100 ?m, a relative flow index of 7.0 to 30.0, a specific surface area of less than 0.15 m2/g, and a tapped bulk density of 0.80 g/mL or more.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: October 30, 2012
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Masayuki Kakizawa, Hidetoshi Tomiyama
  • Test system for evaluating the compatibility of biologically active substances with copolymers
    Patent number: 8293374
    Abstract: A test solution agent, a test system and a method for evaluating the compatibility of biologically active substances with N-vinylpyrdolidone are disclosed.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: October 23, 2012
    Assignee: Abbott GmbH & Co. KG
    Inventors: Joerg Breitenbach, Bernd Liepold
  • Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
    Patent number: 8293272
    Abstract: In a solid pharmaceutical preparation containing water-soluble salts of levothyroxine and/or liothyronine as active ingredients, the water activity of said pharmaceutical preparation is adjusted to values of below 0.4 and, preferably, 0.1 to 0.3, measured at room temperature.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: October 23, 2012
    Assignee: Globopharm Pharmazeutische Produktions-und Handelsgesellschaft m.b.H.
    Inventors: Walter Burghart, Kurt Burghart, Johannes Raneburger
  • Local administration of gallium compositions to treat pain
    Patent number: 8293268
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: October 23, 2012
    Inventor: Lawrence Richard Bernstein
  • Controlled-release nanoparticulate compositions
    Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Controlled release and taste masking oral pharmaceutical composition
    Patent number: 8293273
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: October 23, 2012
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Compositions and methods for body weight management
    Patent number: 8287898
    Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: October 16, 2012
    Assignee: The Procter & Gamble Company
    Inventors: Ronald James Jandacek, Gary Robert Kelm, Satinder Singh Bharaj, Jorge Villanueva Penafiel
  • Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
    Patent number: 8288342
    Abstract: The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: October 16, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Sundeep Sethia, Kathleen Reape, Howard Hait, Carole S. Ben-Maimon
  • PHARMACEUTICAL CO-CRYSTALS OF QUERCETIN
    Publication number: 20120258170
    Abstract: A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.
    Type: Application
    Filed: March 19, 2012
    Publication date: October 11, 2012
    Applicant: Nutracryst Therapeutics Private Limited
    Inventors: Anil Kumar KRUTHIVENTI, Iqbal Javed, Satyanarayana Reddy Jaggavarapu, RaviKumar Nagalapalli, Ganesh Saraswatula Viswanadha, Solomon Kamalakaran Anand
  • Probiotic Compositions, Methods and Apparatus for Their Administration
    Publication number: 20120247993
    Abstract: A probiotic composition including a probiotic microorganism embedded within a matrix, the matrix substantially maintaining the viability of said microorganisms. The matrix releases said microorganisms into and upon contact with a liquid carrier. The invention includes methods for manufacturing the composition, particular forms of the composition (2) and as apparatus for administration.
    Type: Application
    Filed: November 13, 2009
    Publication date: October 4, 2012
    Applicant: UNISTRAW PATENT HOLDINGS LIMITED
    Inventors: Ken Palazzi, Mark Styan, Kristel Wallis, Jenni Sofjan, Yin Li, Patricia Conway
  • Enteric-coated HT-2157 compositions and methods of their use
    Patent number: 8277842
    Abstract: Drug compositions comprising the compound HT-2157 and their therapeutic uses, including the treatment of CNS disorders and cognitive impairments and the modulation of cognitive function, are disclosed. More particularly, the present invention relates to enteric-coated formulations comprising HT-2157 that reduce the appearance of clinically relevant methemoglobinemia relative to administration of non-enteric-coated formulations comprising HT-2157.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: October 2, 2012
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventor: Alan P Kaplan
  • Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including and N-acetyl D-glucosamine
    Patent number: 8278089
    Abstract: Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a sufficient dosage for therapeutic effect, one such formulation being: 50 mg of Lactobacillus delbrueckii subsp bulgaricus lysate strain YB-I 10 mg of N-acetyl D-glucosamine. Excipients can include one or more of, maltodextrin; xanthan gum; acesulfam K; lemon powder and a flavoring, e.g., juice; Mannitol TL-32-04, Microcrystalline Cellulose and Carrageenan, Fructose, PVP-XL TL-11-04, Gellan Gum, Citrus TL 1-04, Orange TL 19-04, Sucrolose TL-13-04, and Mg ST TL-13-04.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: October 2, 2012
    Inventor: Carl Miller
  • Binders for tablets with high strength based on finely divided vinyllactam polymers, the production and use thereof
    Patent number: 8268350
    Abstract: Finely divided binders in powder form composed of vinyllactam polymers, where the binders have an average particle size of up to 35 ?m and an apparent density of less than 0.2 g/ml.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: September 18, 2012
    Assignee: BASF SE
    Inventors: Karl Kolter, Hermann Ascherl, Bernhard Fussnegger
  • Solid pharmaceutical dosage form
    Patent number: 8268349
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: September 18, 2012
    Assignee: Abbott Laboratories
    Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
  • Orally administered agent and an orally administered agent/supporting substrate complex
    Patent number: 8268333
    Abstract: With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: September 18, 2012
    Assignee: Lintec Corporation
    Inventor: Eiji Nogami
  • Aqueous film coating solution, film coated granule and tablet using the same
    Patent number: 8268356
    Abstract: An object of the present invention is to provide an aqueous film coating solution, and the like, which has good acid resistance and sustained release properties as well as the flexibility suitable for the tablet compression force and are highly productive and cost efficient. The aqueous film coating solution of the present invention comprises an ethyl acrylate/methyl methacrylate copolymer dispersion, a methacrylic acid copolymer LD, a plasticizer, titanium oxide and water, wherein the solid mass ratio of the ethyl acrylate/methyl methacrylate copolymer dispersion, the methacrylic acid copolymer LD, the plasticizer and the titanium oxide is 100:(40 to 100):(5 to 50):(5 to 30) and the solid content thereof is 5 to 20 mass %.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: September 18, 2012
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Naoya Yoshida, Yoshihito Yaginuma
  • Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
    Patent number: 8268351
    Abstract: A pharmaceutical matrix film tablet with controlled release of natural mixtures of conjugated estrogens which have been obtained from the urine of pregnant mares.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: September 18, 2012
    Assignee: Abbott Products GmbH
    Inventors: Bernd Thumbeck, Klaus Budde, Gerhard Kristen, Margit Wiards
  • Solid oral sensorial products including stain inhibitor
    Patent number: 8268370
    Abstract: A solid oral sensorial product includes at least one botanical material and at least one phosphate containing stain inhibitor. The botanical material is selected from the group consisting of tobacco, tea, coffee, cocoa, and combinations thereof.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 18, 2012
    Assignee: Philip Morris USA Inc.
    Inventors: Donald E. Miser, William R. Sweeney, Qinglin Li, Jerome A. Merski
  • Modified release composition for highly soluble drugs
    Patent number: 8268352
    Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: September 18, 2012
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
  • PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN
    Publication number: 20120231076
    Abstract: The invention relates to pharmaceutical compositions comprising rivaroxaban, suitable for immediate release, and processes of preparing such compositions, preferably by a melt-granulation process or by a specific direct-compression process.
    Type: Application
    Filed: October 5, 2010
    Publication date: September 13, 2012
    Applicant: Ratiopharm GmbH
    Inventors: Ralph Stefan, Jana Paetz
  • ABUSE-RESISTANT OPIOID DOSAGE FORM
    Publication number: 20120231075
    Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 13, 2012
    Applicant: Endo Pharmaceuticals Inc.
    Inventors: Huai-Hung Kao, Yadi Zeng, Michelle Howard-Sparks, Fai Jim
  • Wet granulation using a water sequestering agent
    Patent number: 8263122
    Abstract: Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: September 11, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Thomas Sun, Ray Lo
  • Solid pharmaceutical preparation
    Patent number: 8263121
    Abstract: The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from “a solid preparation containing an insulin sensitizer alone as an active ingredient”. The present invention provides a solid preparation containing (1) a layer containing an insulin sensitizer, and (2) a layer containing (a) an active ingredient (except insulin sensitizers), (b) microcrystalline cellulose having a mean particle size of 5-25 ?m, (c) microcrystalline cellulose having a mean particle size of 30-100 ?m and (d) polyvinylpyrrolidone K-90.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: September 11, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiko Koike, Hiroyoshi Koyama, Naoru Hamaguchi
  • Rapidly disintegrating tablet containing polyvinyl alcohol
    Patent number: 8263123
    Abstract: The present invention provides a quickly disintegrating tablet which has quick disintegrability and solubility in an oral cavity, and does not have uncomfortable tastes such as bitterness, has a small variation of a tablet physical property even in storage under a humidifying condition, and has substantially no change in a medicine content in the tablet and tablet appearance and which is superior in stability; and a manufacturing method of the tablet. That is, it provides: a quickly disintegrating tablet which is prepared by blending a medicine with a saccharide and polyvinyl alcohol, which has small variations of tablet weight, tablet hardness, tablet diameter and tablet thickness, and which is superior in medicine stability in the tablet; and a manufacturing method of the tablet.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: September 11, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yutaka Morita, Masanobu Yasui, Takayuki Ohwaki, Yuki Tsushima
  • Orally-dispersible multilayer tablet
    Patent number: 8263126
    Abstract: The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: September 11, 2012
    Assignee: Ethypharm
    Inventors: Pascal Oury, Gael Lamoureux, Catherine Herry, Yann Prevost
  • Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
    Patent number: 8263125
    Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: September 11, 2012
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
  • In vivo use of water absorbent polymers
    Patent number: 8263112
    Abstract: The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e.g. urea, from the G.I. tract.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: September 11, 2012
    Assignee: Sorbent Therapeutics, Inc.
    Inventors: Jaime Simon, Alan D. Strickland
  • BIOEQUIVALENT FORMULATION OF EFAVIRENZ
    Publication number: 20120225121
    Abstract: The present invention provides a suitable technique namely wet milling and the process for reducing the particle size of efavirenz and making a tablet or capsule formulation with desired bioavailability equivalent to the reference listed drug without loosing its characteristics.
    Type: Application
    Filed: November 4, 2009
    Publication date: September 6, 2012
    Applicant: HETERO RESEARCH FOUNDATION
    Inventors: Bandi Parthasarad-Hi Reddy, Podili Khadgapathi, Goli Kamalakar Reddy
  • Pharmaceutical Compositions of Sevelamer
    Publication number: 20120219626
    Abstract: The invention relates to a pharmaceutical immediate release tablet comprising a core comprising 70-85 weight percent of sevelamer carbonate, calculated as an anhydrous compound, 10-25 weight percent of lactose monohydrate and, optionally, a water soluble film coat surrounding the to a process of making such tablets, to their use in medicine, and to the use of polyvinyl alcohol-polyethylene glycol graft copolymer for making such coated tablets.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 30, 2012
    Inventor: Niels Jaap Osinga
  • PROCESS FOR PREPARING PRODUCTS COMPRISING STABILISED ACTIVES AND COMPOSITIONS COMPRISING SAME
    Publication number: 20120219624
    Abstract: The present invention broadly relates to a process for preparing products comprising active components, and in particular biological materials, wherein the active components are stabilised. The invention further relates to compositions comprising the products, and in particular compositions comprising therapeutic biological materials.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 30, 2012
    Inventor: Sai Ying Ko
  • Composition with Enhanced Thermogenic Activity and the Use Thereof in the Prevention and Treatment of Obesity
    Publication number: 20120219621
    Abstract: A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity Pharmaceutical compositions of a dietary supplement or medical device, useful for the treatment and prevention of overweight and obesity and metabolic syndrome comprising: a) menthol or a peppermint essential oil comprising menthol, in association with one or more components having a thermogenetic activity, selected from: b1) capsaicin or a capsacinoid derived from Capsicum genus or a Capsicum extract containing capsaicin and/or capsacinoids; b2) a sulphur containing active principle derived from the Allium genus or an Allium extract containing it; b3) a catechin active substance derived from the genus Camellia or a Camellia extract containing it. The menthol and mint essential oil have a potentiating action on the biological activities of the other aforementioned components.
    Type: Application
    Filed: October 11, 2010
    Publication date: August 30, 2012
    Applicant: MEDESTEA BIOTECH S.P.A.
    Inventor: Mariana Gabriela Alvarez Favela
  • Bioadhesive drug formulations for oral transmucosal delivery
    Patent number: 8252328
    Abstract: Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: August 28, 2012
    Assignee: Acelrx Pharmaceuticals, Inc.
    Inventors: Stelios Tzannis, Pamela Palmer, Thomas Schreck, Larry Hamel, Andrew I. Poutiatine
  • Bioadhesive drug formulations for oral transmucosal delivery
    Patent number: 8252329
    Abstract: Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 28, 2012
    Assignee: Acelrx Pharmaceuticals, Inc.
    Inventors: Stelios Tzannis, Larry Hamel, Pamela Palmer, Thomas Schreck, Andrew I. Poutiatine
  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20120213846
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 23, 2012
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA
    Publication number: 20120213847
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: February 10, 2012
    Publication date: August 23, 2012
    Applicant: ZS Pharma, Inc.
    Inventors: Donald Jeffrey Keyser, Alavaro F. Guillem
  • CALCIUM CARBONATE GRANULATION
    Publication number: 20120213849
    Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 23, 2012
    Applicant: DELAVAU L.L.C.
    Inventors: Kevin W. Lang, James W. Dibble, Raya Levin, Gregory B. Murphy
  • Controlled release and taste masking oral pharmaceutical composition
    Patent number: RE43799
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: November 13, 2012
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati